Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...

Journal of Bioresources and Bioproducts reports that a phenol-rich, low-molecular lignin fraction (F3) obtained by simple ...

Learn why genetic mutation testing should be the first step in cancer diagnosis and how it leads to precise, life-saving ...

The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...

The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...

An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only manageable grade 1 to 2 toxicities and no cardiovascular or bleeding ...

Rigel completed enrolment for the dose escalation phase in July 2025 and expects to share updated data later this year.

The first global consensus on inflammatory bowel disease and pregnancy delivers clinician-focused, evidence-based guidance ...

Patients who progressed on first- or second-line therapy were the population evaluated in the CABINET trial (NCT03375320). Anthony suggests that patients with pancreatic and pulmonary NETs, ...

Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY(R)) for the treatment of subjects with moderately to severely ...

OTX-TKI (Axpaxli) offers a novel approach for wet macular degeneration with sustained drug release up to 9 months via a ...